Your search returned 8 results.

Results
	1.	Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors: Swain, Sandra M PMID: 36944848 Year: 2023 Citation: Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun. Department: Associate Dean for Research Development MedStar Health Medline publication type: Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G DOI: https://dx.doi.org/10.1007/s10549-023-06881-8 Add to cart (remove)
	2.	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors: Swain, Sandra M PMID: 26272770 Year: 2015 Citation: Lancet Oncology. 16(9):1037-48, 2015 Sep. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1016/S1470-2045(15)00041-8 Add to cart (remove)
	3.	NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. MedStar authors: Swain, Sandra M PMID: 32371537 Year: 2020 Citation: Clinical Cancer Research. 26(16):4233-4241, 2020 08 15. Institution: MedStar Health Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Bandos H, Brauer HA, Geyer CE Jr, Goerlitz DS, Harris BT, Lucas PC, Mamounas EP, Rastogi P, Ren Y, Robidoux A, Swain SM, Tang G, Wolmark N DOI: https://dx.doi.org/10.1158/1078-0432.CCR-20-0152 Add to cart (remove)
	4.	Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review] MedStar authors: Swain, Sandra M PMID: 23530718 Year: 2013 Citation: Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Review Form of publication: Journal Article All authors: O'Sullivan CC, Swain SM DOI: http://dx.doi.org/10.1517/14712598.2013.783007 Add to cart (remove)
	5.	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors: Swain, Sandra M PMID: 27693116 Year: 2017 Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N DOI: https://dx.doi.org/10.1016/j.clbc.2016.07.008 Add to cart (remove)
	6.	Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. [] MedStar authors: Swain, Sandra M PMID: 25542269 Year: 2015 Citation: Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Bhatt K, Bury MJ, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Goel R, Jacobs SA, Johannes H, Julian TB, Mamounas EP, Provencher L, Rastogi P, Robidoux A, Stella PJ, Swain SM, Tan AR, Thirlwell MP, Wolmark N DOI: http://dx.doi.org/10.1007/s10549-014-3221-2 Add to cart (remove)
	7.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	8.	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors: Swain, Sandra M PMID: 24095300 Year: 2013 Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1016/S1470-2045(13)70411-X Add to cart (remove)

Powered by Koha